The Government announced on October 13 that clinically extremely vulnerable people in England will receive new guidance to help them reduce their risk from coronavirus, tailored to where they live.
The guidance will be tied into the new local COVID alert levels framework, meaning those at the highest risk of serious illness from the virus will receive specific advice depending on the level of risk in their local area, as coronavirus rates continue to rise.
With many national measures now in place that apply to everyone – for example, the rule of 6 and mandatory face coverings – the clinically extremely vulnerable group is already helped by wider protection measures not previously in place when shielding was originally introduced in March.
These additional precautions set out on October 13, recommended by the Deputy Chief Medical Officer (DCMO) for England, will ensure an extra layer of protection specifically adapted to people’s locations and level of risk, as dictated by the local COVID alert levels.
More information can be found on the Government website.
Who is in the clinically extremely vulnerable group?
Those with the following conditions fall into the clinically extremely vulnerable group:
- solid organ transplant recipients
- people with specific cancers:
- people with cancer who are undergoing active chemotherapy
- people with lung cancer who are undergoing radical radiotherapy
- people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment
- people having immunotherapy or other continuing antibody treatments for cancer
- people having other targeted cancer treatments that can affect the immune system, such as protein kinase inhibitors or PARP inhibitors
- people who have had bone marrow or stem cell transplants in the last 6 months or who are still taking immunosuppression drugs
- people with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD)
- people with rare diseases that significantly increase the risk of infections (such as severe combined immunodeficiency (SCID), homozygous sickle cell)
- people on immunosuppression therapies sufficient to significantly increase risk of infection
- women who are pregnant with significant heart disease, congenital or acquired
- other people who have also been classed as clinically extremely vulnerable, based on clinical judgement and an assessment of their needs. GPs and hospital clinicians have been provided with guidance to support these decision
Last updated: Mon 19th October, 2020 @ 17:04